Neutropenia Clinical Trial
— MB-6Official title:
The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.
This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal cancer who underwent surgical excision of their primary tumor.
Status | Recruiting |
Enrollment | 184 |
Est. completion date | December 31, 2022 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Men or women 20 years of age or older. 2. Histologically or cytologically confirmed stage 3 colorectal adenocarcinoma. 3. Complete resection of the primary tumor without gross or microscopic evidence of residual disease. 4. No more than 8 weeks have elapsed from the time of surgery and have recovered from the effects. 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) < 2 at the time of screening. 6. Hematological function: ANC=1500/mm3, Hemoglobin =9.0 g/dL, Platelet count =100000/mm3. 7. Kidney function:Serum creatinine <2 mg/dL. 8. Liver function: AST =3 times ULN, ALT =3 times ULN, Total Bilirubin =2 times ULN. 9. Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines. 10. Men and women of childbearing potential must agree to employ adequate contraception during the study period. Exclusion Criteria: 1. History of second primary malignancies except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix. 2. Systemic chemotherapy, immune therapy or experimental or approved antibodies/proteins (e.g. bevacizumab) administered after surgery and prior to randomization. 3. Concurrent treatment with any other anticancer therapy. 4. Radiotherapy =14 days prior to randomization. 5. Any unresolved toxicity > CTC (Common Toxicity Criteria) grade 1 from previous anti-cancer therapy (including radiotherapy) except haematological toxicity and alopecia. 6. Patients with congestive heart failure, epilepsy, or other significant medical conditions as judged by the investigator. 7. Contraindications to FOLFOX chemotherapy: peripheral neuropathy NCI CTC >1, liver failure, uncontrolled coronary heart disease, myocardial infarction within the previous 6 months before randomization. 8. Patient of child-bearing potential is evidently pregnant or is breast feeding. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Microbio Co., Ltd. | Taipei |
Lead Sponsor | Collaborator |
---|---|
Microbio Co Ltd |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3. | The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy, defined as an absolute neutrophil count (ANC)<500/mm3 | 18 weeks | |
Secondary | Time to first Grade 4 Neutropenia | To determine the time interval from randomization to the first episode of grade 4 Neutropenia.
The analyses for incidence of study event will be conducted using logistic regression model method to adjust for gender and the regimen of chemotherapy (e.g., FOLFOX4 or FOLFOX6). |
18 weeks | |
Secondary | Incidence of Febrile Neutropenia | The febrile neutropenia is defined as an ANC <1000/mm3 and a single temperature =38.3 degree of C or a sustained temperature of =38.0 degree C for more than one hour. | 18 weeks | |
Secondary | Incidence of Grade 3 or 4 Neutropenia | The grade 3 or 4 neutropenia during the chemotherapy period is defined as an absolute neutrophil count (ANC) <1000/mm3. | 18 weeks | |
Secondary | Change in Serum Creatinine level | Any change in Serum Creatinine level during the chemotherapy period | 18 weeks | |
Secondary | Health-Related Quality of Life (HRQoL) - QLQ-C30 | Health-Related Quality of Life (HRQoL) - QLQ-C30 should be completed at baseline, day 71 and end of study. | 18 weeks | |
Secondary | Quality of Life -VAS on Fatigue, Constipation, Appetite | Quality of Life -VAS on Fatigue, Constipation, Appetite will be assessed by patients every two weeks until end of study. | 18 weeks | |
Secondary | Compliance with Chemotherapy | The compliance with chemotherapy will be summarized by descriptive statistic and listed by each cycle and overall period. | 18 weeks | |
Secondary | Increase in Body Weight | Any increased body weight during the chemotherapy period. | 18 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02452034 -
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
|
Phase 1 | |
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT00020865 -
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
|
Phase 3 | |
Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
Completed |
NCT00020371 -
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
|
Phase 1 | |
Terminated |
NCT00005787 -
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Not yet recruiting |
NCT02238873 -
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
|
Phase 3 | |
Completed |
NCT01058993 -
AMD 3100 for Treatment of Myelokathexis
|
Phase 1 | |
Completed |
NCT00771810 -
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
|
Phase 2 | |
Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
Completed |
NCT00770172 -
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT00771433 -
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00030758 -
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
|
Phase 4 | |
Completed |
NCT00001790 -
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
|
Phase 1 | |
Completed |
NCT00002693 -
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT04154488 -
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
|
Phase 1/Phase 2 |